246 related articles for article (PubMed ID: 22077794)
1. Fotemustine for the treatment of melanoma.
Quéreux G; Dréno B
Expert Opin Pharmacother; 2011 Dec; 12(18):2891-904. PubMed ID: 22077794
[TBL] [Abstract][Full Text] [Related]
2. [Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
Perrot JL; Lanthier K; Benoit F; Graille MC; Guy C; Bertheas MF; Cambazard F
Ann Dermatol Venereol; 1995; 122(10):663-6. PubMed ID: 8687048
[TBL] [Abstract][Full Text] [Related]
3. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
4. Fotemustine in the treatment of brain primary tumors and metastases.
Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
[TBL] [Abstract][Full Text] [Related]
5. [Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
Pathol Biol (Paris); 1990 Oct; 38(8):876-80. PubMed ID: 2274396
[No Abstract] [Full Text] [Related]
6. [Fotemustine: muphoran].
Avril MF
Ann Dermatol Venereol; 2007 Dec; 134(12):997-1000. PubMed ID: 18166925
[No Abstract] [Full Text] [Related]
7. [Contribution of a new nitrosourea compound: fotemustine].
Boaziz C
Pathol Biol (Paris); 1992 Dec; 40(9 Pt 2):964-8. PubMed ID: 1338920
[TBL] [Abstract][Full Text] [Related]
8. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.
Schallreuter KU; Wenzel E; Brassow FW; Berger J; Breitbart EW; Teichmann W
Cancer Chemother Pharmacol; 1991; 29(1):85-7. PubMed ID: 1742855
[TBL] [Abstract][Full Text] [Related]
9. [New toxicity of fotemustine: diffuse interstitial lung disease].
Bertrand M; Wémeau-Stervinou L; Gauthier S; Auffret M; Mortier L
Ann Dermatol Venereol; 2012 Apr; 139(4):277-81. PubMed ID: 22482481
[TBL] [Abstract][Full Text] [Related]
10. Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma.
Pontes L; Lopes M; Ribeiro M; Santos JG; Azevedo MC
Melanoma Res; 1997 Oct; 7(5):417-9. PubMed ID: 9429225
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
Del Vecchio M; Mortarini R; Canova S; Di Guardo L; Pimpinelli N; Sertoli MR; Bedognetti D; Queirolo P; Morosini P; Perrone T; Bajetta E; Anichini A
Clin Cancer Res; 2010 Dec; 16(23):5862-72. PubMed ID: 21030496
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma.
Gill S; Shapiro J; Westerman D; Prince HM
J Clin Oncol; 2007 Oct; 25(28):4493-4. PubMed ID: 17906211
[No Abstract] [Full Text] [Related]
13. Persistent thrombocytopenia during melanoma treatment with fotemustine.
Turrisi G; Sozzi P; Marinozzi C; Clerico MA
Melanoma Res; 2006 Dec; 16(6):543-4. PubMed ID: 17119456
[TBL] [Abstract][Full Text] [Related]
14. [Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
Célérier P; Dreno B; Bureau B; Litoux P
Ann Dermatol Venereol; 1993; 120(6-7):437-40. PubMed ID: 8279787
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC.
Addeo R; Zappavigna S; Luce A; Facchini S; Caraglia M
Expert Opin Drug Saf; 2013 Sep; 12(5):729-40. PubMed ID: 23560594
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide in combination with fotemustine in patients with metastatic melanoma.
Tas F; Camlica H; Topuz E
Cancer Chemother Pharmacol; 2008 Jul; 62(2):293-8. PubMed ID: 17909803
[TBL] [Abstract][Full Text] [Related]
17. Treatment of metastatic uveal melanoma with intravenous fotemustine.
Spagnolo F; Grosso M; Picasso V; Tornari E; Pesce M; Queirolo P
Melanoma Res; 2013 Jun; 23(3):196-8. PubMed ID: 23624366
[TBL] [Abstract][Full Text] [Related]
18. Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
Khayat D; Avril MF; Gerard B; Bertrand P; Bizzari JP; Cour V
Melanoma Res; 1992 Sep; 2(3):147-51. PubMed ID: 1450667
[TBL] [Abstract][Full Text] [Related]
19. Neurological toxicity during metastatic melanoma treatment with fotemustine.
Khalil Z; Pageot N; Carlander B; Guillot B
Melanoma Res; 2005 Dec; 15(6):563-4. PubMed ID: 16314745
[TBL] [Abstract][Full Text] [Related]
20. Sequential interferon-alpha2b, interleukin-2 and fotemustine for patients with metastatic melanoma.
Terheyden P; Becker JC; Kämpgen E; Bröcker EB
Melanoma Res; 2000 Oct; 10(5):475-82. PubMed ID: 11095409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
